Patrick Feeley

JPMorgan said in a note it views the ongoing legal battle between payors, dialysis providers and the American Kidney Fund as a major overhang for Davita Inc (NYSE: DVA) shares. As such, the firm downgraded shares of DaVita from Neutral to Underweight and lowered its price target from $66 to $51....